Prelude Corp announced it raised $10 Million in an initial filing from an offering of $10 Million

Company

Location

About

PreludeDx is a precision diagnostics company dedicated to providing actionable tools for managing early-stage breast cancer. Its first test, DCISionRT, is the result of over a decade of research focused on DCIS and was developed using technology licensed from the University of California, San Francisco. Designed to address the critical question faced by DCIS patients — What is my risk of recurrence, and what treatment is appropriate? — DCISionRT helps personalize treatment decisions with confidence.